QuantAbundanciaAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

23,306 signal articles · 380 in last 24h · 111,195 total before filter · latest 15m ago
380last 24h
2299last 7d
408● bullish (7d)
216● bearish (7d)
203publishers
AllMacro273Earnings1374M&A94Regulatory20Product15Analyst19
✕ clear all filterssentiment: neutralSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
MACOM Technology Solutions Q3 Earnings Call Highlights
MarketBeat5d agoneutral
MACOM Technology Solutions Q3 Earnings Call Highlights

MACOM Technology Solutions (NASDAQ:MTSI) reported record fiscal third-quarter results, citing strong demand across its data center, industrial and defense, and telecom markets. The company also issued fourth-quarter guidance that calls for another sequential increase in revenue, margins and adjusted

Lexicon Pharmaceuticals Q2 Earnings Call Highlights
MarketBeat5d agoneutral
Lexicon Pharmaceuticals Q2 Earnings Call Highlights

Lexicon Pharmaceuticals (NASDAQ:LXRX) reported a wider second-quarter loss as revenue declined sharply from the prior-year period, while the company highlighted completed enrollment in its Phase III SONATA-HCM trial and outlined plans to resubmit a new drug application for ZYNQUISTA in type 1 diabet

MKS Q2 Earnings Call Highlights
MarketBeat5d agoneutral
MKS Q2 Earnings Call Highlights

MKS (NASDAQ:MKSI) reported second-quarter 2026 revenue of $1.25 billion, up 16% sequentially and 28% from a year earlier, as demand increased across semiconductor, electronics and packaging, and specialty industrial markets. Management said revenue and key profitability measures reached the high end

Lightbridge Q2 Earnings Call Highlights
MarketBeat5d agoneutral
Lightbridge Q2 Earnings Call Highlights

Lightbridge (NASDAQ:LTBR) reported progress in its nuclear fuel development program during the second quarter and first half of 2026, including the removal of its first irradiated fuel material samples from Idaho National Laboratory’s Advanced Test Reactor and steps toward commercial-scale fabricati

Ligand Pharmaceuticals Q2 Earnings Call Highlights
MarketBeat5d agoneutral
Ligand Pharmaceuticals Q2 Earnings Call Highlights

Ligand Pharmaceuticals (NASDAQ:LGND) reported second-quarter 2026 results marked by higher royalty revenue and adjusted earnings, while highlighting the post-quarter close of its XOMA Royalty acquisition and a $700 million zero-coupon convertible-note offering. Total revenue rose 34% year over year

Investing.com5d agoneutral
Atlassian rockets 23% after crushing earnings and flexing cloud & AI muscle

The company posted adjusted earnings per share of $1.87, beating the analyst consensus of $1.50 by $0.37. Revenue reached $1.77 billion, surpassing the $1.66 billion estimate and representing a 28% increase YoY from $1.38 billion in the same quarter last year. Cloud revenue grew 31% YoY to $1.21 billion, while Data Center revenue came in at $461.9 million, above the $414.6 million estimate.

U.S. Stocks Down on Hormuz Deal Doubts
The Wall Street Journal5d agoneutral
U.S. Stocks Down on Hormuz Deal Doubts

U.S. stocks fell in a jittery session amid doubts about the reopening of the Strait of Hormuz. The broad S&P 500 lost 13.59 points, or 0.18%, to 7709.96 and the tech-heavy Nasdaq Composite declined 15.09 points, or 0.06%, to 26348.35. U.S.-traded oil futures gained $2.07, or 2.8%, to $77.29 a barrel as trepidation about the Strait of Hormuz grew.

Navient (NASDAQ:NAVI) Delivers Impressive Q2 CY2026
StockStory5d agoneutral
Navient (NASDAQ:NAVI) Delivers Impressive Q2 CY2026

Student loan servicer Navient (NASDAQ:NAVI) beat Wall Street’s revenue expectations in Q2 CY2026, but sales fell by 8.5% year on year to $150 million. Its GAAP profit of $0.26 per share was 25.3% above analysts’ consensus estimates.